Summary
HGH Fragment 176-191 is the supplier name for a C-terminal growth hormone fragment that is essentially the same molecule as AOD-9604. Its research base is the AOD-9604 literature: lipolysis in rodents, and a human programme that did not produce meaningful weight loss.
How it works
See AOD-9604. Early studies by Ng and colleagues at Monash University identified the C-terminal region of growth hormone as responsible for lipolytic activity in adipose tissue.
Research use cases
Areas where HGH Fragment 176-191 has been studied. Inclusion here does not mean it works for that purpose.
- Adipose tissue lipolysis in rodent models
What the research found
Origin of the fragment
Studies in the 1990s and 2000s showed that synthetic C-terminal fragments of hGH reduced fat in obese rodents without the diabetogenic effects of full-length growth hormone.1
Safety and open questions
No dedicated human safety studies under this name. Because it overlaps with AOD-9604, those human data are the closest reference point.
Regulatory status
Not approved. Sold for research use.
Status was accurate when this page was last reviewed on October 26, 2026. Regulations change; check with the relevant authority before relying on it.
HGH Fragment 176-191: common questions
Should I treat this as a different compound from AOD-9604?
Chemically they are near-identical. The names reflect marketing history more than pharmacology. The certificate of analysis should state the actual sequence and mass.
Is HGH Fragment 176-191 approved for human use?
Not approved. Sold for research use.
References
- Heffernan M, Summers RJ, Thorburn A, et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology.
Links open a PubMed search for the exact title, or the original source where one is given.